20:07 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a key...
20:20 , Jun 29, 2018 |  BC Extra  |  Company News

CHMP backs CAR Ts, Orphan candidates

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
18:35 , Jun 26, 2018 |  BC Extra  |  Company News

Puma: CHMP reversing course to favor neratinib's approval

Puma Biotechnology Inc. (NASDAQ:PBYI) said EMA's CHMP is likely to recommend approval of oral neratinib as extended adjuvant treatment of early stage, hormone receptor-positive, HER2-positive breast cancer. The company's shares were up $12.45 (24%) to...
22:54 , Jun 20, 2018 |  BC Extra  |  Preclinical News

Broad ErbB inhibition arrests KRAS mutant cancer

Multi-ErbB inhibitors may provide a treatment option for K-Ras (KRAS)-driven lung cancer where ErbB family member EGFR1-specific therapies have failed, according to two studies published in Science Translational Medicine on Wednesday. The findings suggest a way...
19:10 , May 18, 2018 |  BC Week In Review  |  Clinical News

First-line NSCLC data reported ahead of ASCO

Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co. (NYSE:BMY) each reported Phase III data for their first-line non-small cell lung cancer (NSCLC) programs in abstracts released ahead of the American Society...
23:27 , May 16, 2018 |  BC Extra  |  Clinical News

First-line NSCLC data reported ahead of ASCO

Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co. (NYSE:BMY) each reported Phase III data for their first-line non-small cell lung cancer programs in abstracts released ahead of the American Society of...
23:17 , May 11, 2018 |  BioCentury  |  Finance

Aslan’s insiders

A disappointing offering on NASDAQ by Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) looks to be the consequence of Taiwan exchange rules that prevented more robust insider participation. So even though big names such as Morningside and...
17:25 , May 11, 2018 |  BC Week In Review  |  Financial News

Aslan lists on NASDAQ

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) raised $42.2 million through the sale of 6 million shares at $7.03 in a NASDAQ listing underwritten by Leerink, Piper Jaffray, BTIG, H.C. Wainwright and CLSA. The price values Alsan...
20:18 , May 10, 2018 |  BC Extra  |  Company News

Puma sinks on delayed Ph III readout

Puma Biotechnology Inc. (NASDAQ:PBYI) said Thursday in its 1Q18 earnings report that data from the Phase III NALA trial are not expected until 4Q18 due to a slower than expected event rate. On March 1,...
16:34 , May 4, 2018 |  BC Extra  |  Financial News

Aslan slips in first trading day on NASDAQ

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) was down $1.42 (20%) to $5.61 in its first day of trading Friday after it raised $42.2 million through the sale of 6 million ADSs at $7.03 in a NASDAQ...